The OHSU Addiction Medicine Section houses a multidisciplinary group of outstanding physicians. Our addiction medicine team is dedicated to serving the people of Oregon. The team provides excellent clinical care for people living with substance use disorders. They also serve the region and the nation through research and education.
Addiction Medicine faculty provide direct services for people living with substance use disorder. Our clinics offer office-based buprenorphine and other medications for treatment of substance use disorders.
Interdisciplinary care at the OHSU hospital
OHSU’s interdisciplinary inpatient addiction medicine consult service (IMPACT) offers initiation of treatment for substance use disorders during hospitalization. People admitted to OHSU for medical and surgical conditions can receive this care. Dr. Honora Englander directs this service.
Getting community care after discharge
The program facilitates linkage to community care upon discharge. Services include medically supervised withdrawal, intensive outpatient, and residential treatment. Community-based faculty are at:
DGIM's HRBR clinic in the news
Read about the wide impact of OHSU's bridge clinic: https://news.ohsu.edu/2022/05/13/ohsu-on-demand-buprenorphine-clinic-reaches-every-corner-of-oregon
Dr. Levander is AMERSA's 2022 New Investigator of the Year!
Read more on our main Internal Medicine page:
Addiction medicine faculty advance addiction and pain management education for learners at all training levels, both locally and nationally.
The OHSU Addiction Medicine Fellowship provides intensive training for physicians. Physicians can become experts in treating substance use disorders across all parts of the healthcare spectrum.
The Oregon Addiction Prevention and Education Initiative provides buprenorphine-waiver training to physicians across Oregon. It also provides other addiction-related education.
The addiction medicine program hosts tele-mentoring (ECHO) CME programs under the direction of Dr. Daniel Hoover.
An OHSU study was recently cited in the New York Times.
Read about OHSU's recently published BRAVO study.
OHSU hosts the Western States Node of National Institute on Drug Abuse’s Clinical Trials Network (CTN). This program tests emerging treatments for opioid, methamphetamines and cocaine use disorders.
Faculty collaborate with the Methamphetamines Addiction Research Center (MARC) and Advanced Imaging Research Center (AIRC) at OHSU to conduct methamphetamines research.
Other NIH-funded health services and clinical trials research focuses on improving treatment of opioid use disorder in rural Oregon, nationally and internationally.